In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...
KEYTRUDA, in patients with advanced solid tumors. KVA12123 cleared all six monotherapy dose levels and the second of four cohorts in combination with pembrolizumab. KVA12123 was well tolerated with no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback